Free Trial
NASDAQ:XCUR

Exicure (XCUR) Stock Price, News & Analysis

Exicure logo
$10.34 +0.15 (+1.42%)
Closing price 05/21/2025 03:58 PM Eastern
Extended Trading
$10.43 +0.08 (+0.82%)
As of 05/21/2025 05:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Exicure Stock (NASDAQ:XCUR)

Key Stats

Today's Range
$11.00
$11.00
50-Day Range
$8.44
$14.05
52-Week Range
$1.44
$36.00
Volume
1,696 shs
Average Volume
572,389 shs
Market Capitalization
$65.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

Exicure Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

XCUR MarketRank™: 

Exicure scored higher than 29% of companies evaluated by MarketBeat, and ranked 785th out of 915 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Exicure.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Exicure is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Exicure is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Exicure has a P/B Ratio of 5.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Exicure's valuation and earnings.
  • Percentage of Shares Shorted

    1.15% of the float of Exicure has been sold short.
  • Short Interest Ratio / Days to Cover

    Exicure has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Exicure has recently decreased by 23.27%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Exicure does not currently pay a dividend.

  • Dividend Growth

    Exicure does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.15% of the float of Exicure has been sold short.
  • Short Interest Ratio / Days to Cover

    Exicure has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Exicure has recently decreased by 23.27%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Exicure insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 3.90% of the stock of Exicure is held by insiders.

    • Percentage Held by Institutions

      42.82% of the stock of Exicure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Exicure's insider trading history.
    Receive XCUR Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Exicure and its competitors with MarketBeat's FREE daily newsletter.

    XCUR Stock News Headlines

    The Prophet's Newest Prediction
    A storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.
    See More Headlines

    XCUR Stock Analysis - Frequently Asked Questions

    Exicure's stock was trading at $13.67 on January 1st, 2025. Since then, XCUR stock has decreased by 24.3% and is now trading at $10.3450.
    View the best growth stocks for 2025 here
    .

    Exicure, Inc. (NASDAQ:XCUR) released its quarterly earnings data on Tuesday, March, 18th. The company reported ($3.39) EPS for the quarter.

    Exicure shares reverse split before market open on Tuesday, August 27th 2024. The 1-5 reverse split was announced on Monday, August 26th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

    Shares of XCUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Exicure investors own include Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Tesla (TSLA), Meta Platforms (META), NIO (NIO), Viking Therapeutics (VKTX) and Energy Transfer (ET).

    Company Calendar

    Last Earnings
    3/18/2025
    Today
    5/21/2025
    Next Earnings (Estimated)
    6/04/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:XCUR
    Fax
    N/A
    Employees
    50
    Year Founded
    N/A

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    $-16,910,000.00
    Pretax Margin
    -799.80%

    Debt

    Sales & Book Value

    Annual Sales
    $500,000.00
    Price / Cash Flow
    N/A
    Book Value
    $1.75 per share
    Price / Book
    5.91

    Miscellaneous

    Free Float
    2,504,000
    Market Cap
    $65.36 million
    Optionable
    Not Optionable
    Beta
    3.86
    20 Stocks to Sell Now Cover

    Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

    Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

    Get This Free Report

    This page (NASDAQ:XCUR) was last updated on 5/22/2025 by MarketBeat.com Staff
    From Our Partners